Objective:
To introduce the Via360 surgical system, a new device for glaucoma surgery that combines canaloplasty and trabeculotomy, enhancing surgical precision and patient outcomes through controlled viscodilation.
Approach:
- The Via360 system received FDA clearance in February 2025.
- Surgeons report improved control and efficiency during procedures, with specific metrics indicating enhanced outcomes.
- The device has shown promise in reducing IOP and medication burden in specific patient subgroups, supported by clinical data.
- Potential for catheter misplacement into unintended areas; training and practice can mitigate this risk.
- Requires training for optimal use despite its streamlined design; ongoing support and resources can enhance user proficiency.
Key Findings:
Interpretation:
The Via360 system enhances the capabilities of minimally invasive glaucoma surgery (MIGS) by allowing for customizable treatment options and improved surgical efficiency.
Limitations:
Conclusion:
The Via360 system represents a significant advancement in MIGS, potentially reducing the need for more invasive surgeries and improving patient outcomes, particularly in those with complex glaucoma cases.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.